Ribociclib Improves Survival in Advanced Breast Cancer - NCI
https://www.cancer.gov/news-events/cancer-currents-blog/2021/ribociclib-improves-metastatic-breast-cancer-survival
WebOct 6, 2021 · With longer follow-up, there was a 12.5-month improvement in median overall survival, Dr. Hortobagyi reported at the ESMO meeting. In addition, 52% of those in the ribociclib group were alive 5 years after beginning treatment, compared with 44% in the letrozole-only group.
DA: 92 PA: 20 MOZ Rank: 22